Our Posts

Recent research suggests that proton pump inhibitors (PPIs) may increase the risk of cardiovascular events in heart attack patients. A study of over 56,000 Danish patients found a 29% higher risk of cardiovascular death or rehospitalization for those taking PPIs post-heart attack. Despite previous FDA warnings about PPIs reducing the effectiveness of Plavix, the study indicated no increased risk when both medications were used together. These findings highlight ongoing concerns about the safety of PPIs for heart patients.

Proton pump inhibitors (PPIs), used to treat acid reflux, are linked to severe kidney issues, including kidney failure and chronic kidney disease. Over 160 lawsuits have been consolidated in New Jersey, with more expected. Studies indicate long-term PPI use significantly increases the risk of kidney damage. Despite FDA label updates in 2014, concerns persist about unlisted side effects. Legal actions are underway, with firms like Parker Waichman LLP offering consultations for affected individuals. Limiting PPI use to medically necessary cases is advised due to potential health risks.

Taxotere (docetaxel), a chemotherapy drug, has been linked to permanent hair loss in some patients, particularly women. While hair loss from chemotherapy is usually temporary, Taxotere has caused long-term alopecia in 3-9% of users. This unexpected side effect has led to emotional, social, and economic challenges for affected individuals. Many have pursued legal action against the manufacturer, Sanofi-Aventis, for inadequate warnings about this risk. Despite its effectiveness and shorter treatment duration, some patients might have chosen alternative treatments had they been aware of the potential for permanent hair loss.

Atrium C-QUR Mesh Injury Lawsuits involve litigation against Atrium Medical Corporation for their C-QUR hernia mesh products, which have caused severe complications such as chronic pain, infections, and allergic reactions. The mesh, coated with Omega 3 fatty acids, has been linked to adverse immune responses and other issues. Despite a voluntary recall in 2009, the products remain on the market. Cases are centralized in a multidistrict litigation in New Hampshire, with Parker Waichman LLP seeking compensation for affected patients. The firm offers free consultations and operates on a contingency basis.

Sanofi-Aventis faces around 800 lawsuits in a federal multidistrict litigation (MDL) in Louisiana, with plaintiffs alleging that the chemotherapy drug Taxotere causes permanent hair loss. They claim Sanofi-Aventis knew of this risk but failed to warn patients. The lawsuits highlight that while European and Canadian labels warned of this side effect, U.S. labels did not until 2015. The MDL aims to streamline the legal process, with cases overseen by Judge Kurt Engelhardt. Recent studies and reports have linked Taxotere to persistent alopecia and other severe side effects.

Hundreds of talcum powder ovarian cancer lawsuits are progressing in federal court in Missouri, with trials set to begin on February 6, 2017. Six plaintiffs claim that Johnson & Johnson's talc-based products contributed to their ovarian cancer. Previous cases in St. Louis resulted in multimillion-dollar awards, including punitive damages. Studies have linked talcum powder use in feminine hygiene to increased ovarian cancer risk. Talc, used in various products, has been scrutinized for its potential health risks, particularly when used in the genital area.

Over 350 lawsuits have been filed concerning the breast cancer drug Taxotere, now part of multi-county litigation. Approved by the FDA in 1996, Taxotere was initially sold without warnings about permanent hair loss, a risk later added to its label in 2015 following lawsuits. Research indicates that 9.2% of patients experienced long-term hair loss, and 6.3% reported poor regrowth. Plaintiffs argue that Sanofi Aventis knew of these risks earlier. Support groups have emerged for affected women, and alternative drugs without this side effect are available.

Proton pump inhibitors (PPIs), commonly used for treating heartburn and ulcers, have been linked to an increased risk of bone fractures, particularly in the hip, wrist, and spine. The FDA revised safety labels in 2010 to reflect this risk, especially for long-term users. Studies indicate that the risk is higher in older individuals and those taking higher doses. Patients are advised to weigh the benefits against potential risks and consult healthcare professionals for guidance. Legal assistance is available for those who have suffered fractures potentially related to PPI use.

Patients with metal-on-metal hip replacements face risks like tissue reactions, metal poisoning, and device fractures, often leading to device failure and revision surgeries. Research shows up to 14% may need revision within seven years, compared to 3% for other implants. Parker Waichman LLP is handling lawsuits for affected patients, investigating devices like Biomet M2a, DePuy ASR XL, DePuy Pinnacle, Wright Profemur, Wright Conserve, Stryker MITCH TRH, and Smith & Nephew Birmingham. Affected individuals are encouraged to seek legal evaluation.

Parker Waichman LLP is addressing potential lawsuits against Pfizer for failing to warn about cancer risks associated with Zithromax and Zmax (azithromycin), especially in stem cell transplant patients. The FDA has issued warnings after studies showed azithromycin could cause cancer relapse. The firm emphasizes the importance of financial accountability for pharmaceutical companies and offers legal representation on a contingency fee basis. They highlight their success in securing significant settlements and stress the need for experienced legal support in such cases. Parker Waichman LLP provides 24/7 legal advice and encourages affected individuals to seek compensation.

Parker Waichman LLP is investigating potential lawsuits for users of the Mirena IUD, a contraceptive device made by Bayer Inc. Allegations suggest Bayer used deceptive marketing, leaving many women unaware of serious risks such as uterine perforation, pseudotumor cerebri, and other complications. The U.S. Judicial Panel on Multidistrict Litigation has centralized related lawsuits in New York due to the growing number of cases. Plaintiffs claim inadequate warnings about the risks, while Bayer opposes centralization, arguing for informal coordination. The investigation aims to hold Bayer accountable for these alleged risks and marketing practices.

A study by the Australian National University, led by Dr. Yingxi Chen, found that using heartburn drugs like proton pump inhibitors (PPIs) increases the risk of infectious gastroenteritis by 70%. This risk is particularly high for individuals over 45. PPIs reduce stomach acid, allowing harmful bacteria and viruses to survive. With nearly 20 million prescriptions annually in Australia, the study highlights the importance of understanding PPI side effects. Overprescription is a concern, with many prescriptions deemed unnecessary. Patients should consult doctors about PPI use, especially the elderly and those with chronic bowel issues.

Carole, a breast cancer survivor, is suing Sanofi-Aventis, the maker of the chemotherapy drug Taxotere, for causing her permanent hair loss. She claims neither she nor her doctor was informed of this risk, despite the company allegedly knowing about it since 2005. Taxotere, marketed as a superior treatment, has been linked to permanent hair loss in 3 to 9 percent of women. Carole's lawsuit highlights the psychological and financial impacts of her condition, as well as the lack of disclosure in the U.S. compared to other countries.

Janssen Pharmaceuticals and Johnson & Johnson face a lawsuit alleging that Invokana, a type 2 diabetes medication, caused an Ohio man's kidney failure. The plaintiff claims the companies concealed the drug's risks, leading to his severe injuries and ongoing health issues. He seeks damages for pain, suffering, and economic losses. Invokana, approved by the FDA in 2014, is linked to serious side effects, including kidney damage, heart attacks, and diabetic ketoacidosis. The lawsuit highlights the need for proper risk disclosure by pharmaceutical companies.

A review by the FDA in April 2015 highlighted that AstraZeneca's diabetes drug, Onglyza, may significantly increase the risk of all-cause mortality. Despite generating substantial sales, concerns arose from the SAVOR study, which linked Onglyza to a 27% increased risk of heart failure hospitalization. The FDA delayed a combination drug launch involving Onglyza, seeking more data. Legal actions are underway for adverse reactions, including death. The FDA's advisory meeting could lead to a Black Box warning, potentially impacting Onglyza's sales.

A multidistrict litigation has been filed against Bayer Healthcare Pharmaceuticals in the Southern District of New York concerning the Mirena® IUD. Plaintiffs allege the device has a flawed design, leading to serious injuries and even death, and claim Bayer failed to adequately warn users of these risks. The litigation includes 75 cases in New Jersey and 50 in federal courts nationwide, with numbers expected to rise. The FDA has identified severe side effects, including uterine perforation and ectopic pregnancy. Bayer was previously reprimanded for downplaying risks in its marketing.

Victims of the defective DePuy Orthopaedics ASR metal-on-metal hip implant may soon lose the opportunity to file lawsuits due to the expiration of the two-year statute of limitations in many states. The ASR implant, recalled in August 2010, has been linked to severe health issues, including device failure and toxic metal accumulation. Over 6,000 lawsuits have been filed, with many consolidated in Ohio federal court. DePuy may attempt to block future lawsuits based on these limitations. Settlements have been reached in some cases, but many victims continue to seek legal action.

The gout medication Uloric, also known as febuxostat, has been linked to severe side effects such as rhabdomyolysis, liver failure, kidney damage, and bone marrow failure. These conditions can lead to serious health complications and even death. Parker Waichman LLP is pursuing legal action against the manufacturer, Takeda Pharmaceuticals, to seek compensation for affected individuals. The firm offers free consultations to those who have experienced adverse effects from Uloric, aiming to provide legal guidance and support for potential claims.

A recent court ruling in California has opened the door for more lawsuits against Bayer over its Essure sterilization device. Women across the U.S. claim Essure caused severe injuries, including pain and organ perforation. Despite Bayer's attempts to dismiss 11 lawsuits, Judge Winifred Y. Smith sided with the plaintiffs, potentially holding Bayer accountable. Essure, approved in 2002, has been linked to over 5,000 adverse events. The FDA has since advised a black box warning, and concerns about its safety persist.

Parker Waichman LLP's Taxotere Lawsuit Attorneys are committed to helping victims of personal injuries, who face pain, emotional distress, and high medical costs. The firm is nationally recognized for its dedicated client representation. They urge potential clients to act quickly to avoid losing their rights. Contact them at 1-800-YOURLAWYER (1-800-968-7529) or fill out a free consultation form to discuss your rights and claim options with an experienced lawyer.

Invokana, a type 2 diabetes drug, was approved by the FDA in 2013 and the EMA shortly after. Despite significant sales growth, serious side effects, including increased amputation risks, were identified. In 2017, the FDA mandated "Boxed Warnings" on canagliflozin drugs like Invokana and Invokamet. Parker Waichman LLP represents clients affected by these side effects, urging those impacted to seek legal advice due to potential compensation for damages. The EMA also issued warnings about SGLT2 inhibitors, including canagliflozin, dapagliflozin, and empagliflozin, linked to amputations.

Parker Waichman LLP offers experienced legal representation for defective product and medical device lawsuits. They provide free, no-obligation case evaluations to discuss potential claims. Prompt action is advised to avoid forfeiting legal rights. Contact them at 1-800-YOURLAWYER or fill out their consultation form to have an experienced lawyer discuss your case and options.

The U.S. FDA has confirmed a link between breast implants and an increased risk of anaplastic large cell lymphoma. Parker Waichman LLP's breast implant illness attorneys are dedicated to empowering clients diagnosed with this cancer to seek justice against major corporations. They offer experienced legal representation to help clients file claims and move forward with their lives. Individuals with breast implants diagnosed with anaplastic large cell lymphoma, non-Hodgkin's lymphoma, or T-cell lymphoma can contact Parker Waichman for a free consultation to explore their legal options.

The FDA is strengthening warning labels on four diabetes drugs, including canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR), due to increased risks of acute kidney injury. From March 2013 to October 2015, 101 cases were confirmed, with four fatalities and many requiring intensive care. Patients are advised not to stop medication without consulting a doctor. The FDA also noted a link between canagliflozin and increased amputation risk. Health professionals should exercise caution, especially for patients with kidney issues.